Eton Pharmaceuticals Inc. (ETON) exhibits 53.5% gross margins and -0.9% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 24.0x enterprise multiple and 4.8% implied options volatility.
Sustained 53.5% gross profitability converts into -1.1% operating margin and -0.9% ROIC, outpacing sector cost of capital.
ROIC: -0.9% // GM: 53.5%YoY revenue trajectory of +104.9% paired with 0.66% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +104.9% // FCF YLD: 0.66%Altman Z-Score of 13.37 and Piotroski F-Score of 7/9 indicate low near-term refinancing stress.
ALTMAN Z: 13.37 // F-SCORE: 7/9Trading at 24.0x trailing P/E (— Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: —Options market prices a ±5.2% implied move with a 0.85 put/call ratio around $53.67 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend -5.8% net margins.
NET MARGIN: -5.8% // D/E: 0.83x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for ETON & activate live FRED threshold breach alerts.